Source Paper
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V <sub>1b</sub> receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Guy Griebel, Jacques Simiand, Claudine Serradeil-Le Gal, Jean Wagnon, Marc Pascal et al.
Proceedings of the National Academy of Sciences • 2002
Chronic Mild Stress Model
Objective: To evaluate antidepressant-like and anxiolytic-like effects of SSR149415 in the chronic mild stress (CMS) model, measuring improvements in physical state, anxiety, despair, and coping behavior degradation produced by stress
Gather these items before starting the experiment. Check off items as you prepare.
Materials1
Sanofi-Synthelabo Recherche • Not specified • Not specified • Not specified
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Chronic Mild Stress Exposure
Mice exposed to chronic mild stress conditions over extended period
Note: CMS model used to induce depression-like symptoms including degradation of physical state, anxiety, despair, and loss of coping behavior
View evidence from paper
“in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress”
Drug Administration
Repeated intraperitoneal administration of SSR149415 at specified doses
Note: Two dose levels tested: 10 mg/kg and 30 mg/kg via intraperitoneal injection
View evidence from paper
“repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days”
Behavioral Assessment
Evaluation of physical state degradation, anxiety levels, despair, and coping behavior changes
Note: Specific behavioral tests not detailed in provided text
View evidence from paper
“improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress”